Annovis Bio, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Annovis Bio, Inc.
Israeli-based start-up RealView received US FDA 510(k) clearance for its Holoscope-i holographic system used prior to and during interventional procedures.
As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date.
Local Medicare carrier Novitas raised its reimbursement rates for continuous cardiac monitoring, but iRhythm has concluded the rates are still too low and is preparing to discontinue serving this Medicare segment.
Micro-cap Annovis Bio’s lead candidate has shown promise in nine patients with Parkinson’s, and could move into late-stage studies this year.
- Other Names / Subsidiaries
- QR Pharma, Inc.